Hutchison China completes enrollment in late-stage study of fruquintinib in third-line lung cancer, top-line data on tap in Q4 [Seeking Alpha]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Seeking Alpha
Hutchison China completes enrollment in late-stage study of fruquintinib in third-line lung cancer, top-line data on tap in Q4Hutchinson China MediTech Limited (NASDAQ:HCM)completes enrollment in a Phase 3 clinical trial,FALUCA, evaluating fruquintinib in patients with advanced non-small cell lung cancer (NSCLC) in a third-line setting.The primary endpoint is overall survival (OS). Secondary endpoints included progression-free survival, response rate and duration of response. Top-line results should be available in Q4.Fruquintinib is an orally available inhibitor of vascular endothelial growth factor receptors 1,2 and 3.HCM is jointly developing fruquintinib in China with Eli Lilly (NYSE:LLY).Click to subscribe to real-time analytics on HCMNow read:Hutchison China Meditech: Outlook For 2018 »
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly's Q1 [Forbes]Forbes
- Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035: A USD 66.63 Billion Market by 2035, Up From USD 9.03 Billion in 2022 [Yahoo! Finance]Yahoo! Finance
- Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- American Kidney Fund Launches National Kidney Health Equity Media Campaign [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk comes under Senate probe over pricing for weight loss drugs [Seeking Alpha]Seeking Alpha
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website